Objective We recently demonstrated that combination treatment with NS3 protease and NS5B polymerase inhibitors succeeded in eradicating the virus in genotype 1b hepatitis C virus (HCV)-infected mice. In this study, we investigated the effect of combining an NS5A replication complex inhibitor (RCI) with either NS3 protease or NS5B inhibitors on elimination of HCV genotypes 1b, 2a and 2b. Design The effects of Bristol-Myers Squibb (BMS)-605339 (NS3 protease inhibitor; PI), BMS-788329 (NS5A RCI) and BMS-821095 (NS5B non-nucleoside analogue inhibitor) on HCV genotypes 1b and 2a were examined using subgenomic HCV replicon cells. HCV genotype 1b, 2a or 2b-infected human hepatocyte chimeric mice were also treated with BMS-605339, BMS-788329 or BMS-821095 alone or in combination with two of the drugs for 4 weeks. Genotypic analysis of viral sequences was achieved by direct and ultra-deep sequencing. Results Anti-HCV effects of BMS-605339 and BMS-821095 were more potent against genotype 1b than against genotype 2a. In in-vivo experiments, viral breakthrough due to the development of a high prevalence of drug-resistant variants was observed in mice treated with BMS-605339, BMS-788329 and BMS-821095 in monotherapy. In contrast to monotherapy, 4 weeks of combination therapy with the NS5A RCI and either NS3 PI or NS5B inhibitor succeeded in completely eradicating the virus in genotype 1b HCV-infected mice. Conversely, these combination therapies failed to eradicate the virus in mice infected with HCV genotypes 2a or 2b. Conclusions These oral combination therapies may serve as a Peg-alfa-free treatment for patients chronically infected with HCV genotype 1b.
INTRODUCTION
Hepatitis C virus (HCV) infection is a major cause of chronic liver diseases, such as cirrhosis and hepatocellular carcinoma. 1 2 A number of new selective inhibitors of HCV proteins, termed direct-acting antiviral agents (DAA), are currently under development. HCV inhibitors targeting NS3 protease and NS5A and NS5B polymerase activity have proceeded to clinical trials for HCV-infected patients. DAA are used in combination with Peg-alfa and ribavirin because monotherapy with these drugs results in the early emergence of drug-resistant variants. 3 4 As Peg-alfa/ribavirin treatment is frequently associated with serious adverse events, an oral Peg-alfa/ribavirin-free DAA combination therapy would offer an ideal treatment option for chronic hepatitis C patients. The first proof-of-concept study to combine NS3 protease and NS5B inhibitors (INFORM-1) reported that 13 days of this combination treatment achieved robust antiviral suppression in genotype 1 HCV-infected patients, and no evidence of resistance to either compound was observed. 5 Following the INFORM-1 study, we and other groups have also reported that a DAA-only combination comprising NS3 protease inhibitor (PI), Bristol-Myers Squibb (BMS)-650032 (asunaprevir) and NS5A replication complex inhibitor (RCI), BMS-790052 (daclatasvir) can achieve high sustained virological
Significance of this study
What is already known on this subject?
▸ Anti-HCV drug monotherapy for chronic hepatitis C patients often results in viral breakthrough due to the emergence of drug-resistant clones. ▸ Combination treatment of NS3 PI and NS5A
inhibitor can eradicate genotype 1b HCV in chronic hepatitis C patients without interferon.
What are the new findings?
▸ Combination treatment of NS5A inhibitor with either NS3 PI or NS5B inhibitor can eradicate HCV, but the effect differs among HCV genotypes.
How might it impact on clinical practice in the foreseeable future?
▸ Short-term combination of NS5A inhibitor with either NS3 PI or NS5B inhibitor might provide an effective interferon-free treatment for genotype 1b chronic hepatitis C patients; however, the combination treatment might be less effective against genotype 2.
response (SVR) rates in patients with HCV genotype 1b infection. 6 A number of DAA-only combination studies are now entering phase 2 clinical trials. 7 The effect of telaprevir was recently analysed in genotype 2 HCV-infected patients. Fifteen days of telaprevir monotherapy decreased the serum HCV RNA titre by 3.7 log 10 IU/ml, and 3 months of telaprevir plus 24 weeks of Peg-alfa/ribavirin triple therapy resulted in SVR in 100% of genotype 2 HCV-infected patients. 8 However, the effect of Peg-alfa/ribavirin-free DAA combination therapy on genotype 2 HCV has not been reported.
The immunodeficient urokinase-type plasminogen activator (uPA) mouse permits repopulation of the liver with human hepatocytes that can be infected with HCV. 9 This animal model is useful for evaluating anti-HCV drugs such as Peg-alfa and NS3 PI. 10 11 Using this animal model, we recently described the successful elimination of HCV genotype 1b by treatment with a combination of NS3 protease and NS5B inhibitors. 12 In this study, we investigated whether short-term combination treatments with NS5A RCI and either NS3 protease or NS5B site I inhibitors could eliminate HCV in vivo in human hepatocyte chimeric mice, and we compared the efficacy of the drugs against HCV genotype 1 versus genotype 2.
METHODS

Compounds and cells
BMS-605339 (NS3 PI, analogue of asunaprevir), BMS-788329 (NS5A RCI, analogue of daclatasvir) and BMS-821095 (NS5B non-nucleoside analogue inhibitor; NNI) were synthesised by BMS. Huh-7 cells that stably maintain HCV replicons were propagated as subconfluent monolayers in Dulbecco's modified essential medium containing 10% fetal bovine serum, 2 mM L-glutamine, and 0.5 mg/ml geneticin (G418; Invitrogen Corp., Carlsbad, California, USA) at 37°C under 5% carbon dioxide. 13 
Determination of IC 50 in culture systems
The genotype 1b (Con 1) replicon cell line was constructed as described previously.
14 A genotype 2a ( JFH-1) cell line was generated by introducing the JFH-1 sequence from NS3 to NS5B into the genotype 1b (Con 1) backbone. 15 Inhibition of HCV RNA replication by either BMS-605339, BMS-788329 or BMS-821095 for 72 h was monitored using a luciferase reporter assay. Antiviral activities of the compounds, for example, the 50% inhibitory concentration (IC 50 ), were determined as described previously. 16 
Human serum samples
Human serum containing a high titre of HCV genotypes 1b, 2a and 2b was obtained from patients with chronic hepatitis who had given written informed consent to participate in the study. Serum samples were divided into small aliquots and stored in liquid nitrogen until use. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved a priori by the institutional review committee.
Animal treatment
Generation of the uPA +/+ /SCID +/+ mice and transplantation of human hepatocytes were performed as described previously. 17 All mice were transplanted with frozen human hepatocytes obtained from the same donor. All animal protocols described in this study were performed in accordance with the guidelines of the local committee for animal experiments, and all animals received humane care. Infection, extraction of serum samples and killing of animals were performed under ether anaesthesia. Eight weeks after hepatocyte transplantation, mice were injected intravenously with 100 ml of HCV-positive human serum samples. Mice serum samples were obtained every 1 or 2 weeks after HCV infection, and HCV RNA levels were measured.
Treatment of HCV-infected mice with anti-HCV inhibitors
Eight weeks after HCV infection when the mice developed stable viraemia (6-8 log 10 copies/ml), mice were administered orally with one of the following: 75 mg/kg of BMS-605339 (twice a day); 10 or 30 mg/kg of BMS-788329 (once a day); or 30 or 100 mg/kg of BMS-821095 (once a day) for 4 weeks. To analyse the effect of the combination treatment, BMS-788329 was mixed with either BMS-605339 or BMS-821095 and given together as a cocktail. To analyse susceptibility to Peg-alfa, 10 μg/kg of human Peg-alfa (Chugai Pharmaceutical Co. Ltd., Tokyo, Japan) were administered by intramuscular injection twice a week for weeks.
RNA extraction and amplification
RNA extraction, nested PCR and quantitation of HCV by realtime PCR were performed as described previously. 11 12 Briefly, RNA was extracted from serum samples and extracted livers using SepaGene RVR (Sankojunyaku, Tokyo, Japan) and reverse transcribed with a random hexamer and a reverse transcriptase (ReverTraAce; TOYOBO, Osaka, Japan) according to the instructions provided by the manufacturer. Quantitation of HCV complementary DNA was performed using a light cycler (Roche Diagnostic, Japan, Tokyo). The lower detection limit of real-time PCR is 3 log 10 copies/ml.
Sequence analysis
The nucleotide and amino acid sequences of the NS3, NS5A and NS5B regions of HCV were determined by direct sequencing as described previously. 12 The primers used to amplify the NS3 region were as the second (inner) primer pair. The amplified DNA fragments were separated onto a 2% agarose gel and purified using the QIAquick gel extraction kit (Qiagen, Hilden, Germany). Nucleotide sequences were determined using BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems Inc., California, USA). The obtained nucleotide and amino acid sequences were compared with the prototype sequences of genotype 1b HCV-J (GenBank accession no.: D90208) 18 .
Ultra-deep sequencing
We have adapted multiplex sequencing by synthesis to sequence multiple genomes simultaneously using the Illumina genome analyser. Briefly, cDNA was fragmented using sonication, and the resultant fragment distribution was assessed using the Agilent BioAnalyzer 2100 platform. A library was prepared using the Multiplexing sample preparation kit (Illumina Inc., California, USA). Imaging analysis and base calling were performed using Illumina Pipeline software with default settings. The N-terminal 1344 nucleotides of NS3 protease, 1146 nucleotides of NS5A RCI and 1133 nucleotides of NS5B polymerase were analysed. This technique revealed an average coverage depth of over 1000 sequence reads per base pair in the unique regions of the genome. Read mapping to a reference sequence was performed using BWA. 19 Direct sequencing consensus data were used to improve alignment to the reference sequence. Codon counts were merged and analysed using R V.2.14.
Statistical analysis
Mice serum HCV RNA titres were compared using the MannWhitney U test. A p value less than 0.05 was considered statistically significant.
RESULTS
Antiviral activities of BMS-605339, BMS-788329and BMS-821095 in cell culture systems
The inhibitory effects of BMS-605339, BMS-788329 and BMS-821095 on HCV replication were analysed in vitro using HCV replicon cells (genotype 1b, Con 1 and genotype 2a, JFH1 
Peg-alfa treatment on mice infected withHCV genotypes 1 and 2
We first analysed the effect of Peg-alfa on mice infected with HCV genotypes 1 and 2. Mice were injected with 10 5 copies of HCV obtained from patients infected with HCV genotypes 1b, 2a, or 2b. Administration of 10 μg/kg of human Peg-alfa twice a week for 2 weeks resulted in only a 0.53 log 10 decrease in the serum HCV RNA titre in HCV genotype 1b-infected mice (figure 1). In contrast, the same therapy resulted in 1.9 log 10 and 1.5 log 10 decreases in serum HCV RNA titres in mice with HCV genotypes 2a ( p<0.05) and 2b (not significant), respectively. No decline in HCV RNA titre was observed in control mice infected with HCV genotype 1b during this 2-week period (figure 1). These results are consistent with the clinical observation that genotype 2 demonstrates a higher susceptibility to Peg-alfa treatment compared to HCV genotype 1.
Effects of BMS-605339, BMS-788329, or BMS-821095on HCV genotype 1b in mice
We analysed the effect of DAA monotherapy on mice infected with HCV genotype 1b. Nine mice were injected with 10 5 copies of HCV obtained from a patient infected with genotype 1b. Eight weeks after injection when stable viraemia had developed, mice were treated with BMS-605339 (N3PI) (figure 2A), BMS-788329 (NS5A RCI) (figure 2B) or BMS-821095 (NS5B site I inhibitor) (figure 2C) for 4 weeks. Although all BMS-605339 and BMS-788329-treated mice showed an initial reduction of serum HCV RNA titres, all later showed rebound during treatment. Nucleotide analysis by direct sequencing revealed the emergence of a mutation coding for D168E in the NS3 region (NS3 PI-resistant variant) 21 in a BMS-605339-treated mouse (figure 2A), and a mutation coding for Y93H in the NS5A region (NS5A RCI-resistant variant) 14 in a BMS-788329-treated mouse at week 4 of treatment ( figure  2B ). Almost all mice treated with BMS-821095 showed an initial reduction in serum HCV RNA titres, and also showed rebound with the emergence of mutations coding for P495A and P495S in the NS5B region (NS5B site I inhibitor-resistant variant) 22 at week 4 of treatment ( figure 2C ). HCV RNA titre reduction was not obvious in some mice treated with 30 mg/kg of BMS-821095 (figure 2C), suggesting that exposure of this inhibitor at 30 mg/kg dosing was not sufficient to suppress viral replication. Ultra-deep sequence analysis showed the development of a high prevalence of drug-resistant variants in mice sera in the NS3 PI, NS5A RCI-treated mice, and enrichment of pre-existing resistance variants in the NS5B NNI-treated mouse 4 weeks after the beginning of the treatment ( figure 2D ).
Combination treatment of BMS-788329 with either BMS-605339 or BMS-821095 in HCV genotype 1b mice
As monotherapies with either the NS3 PI, or the NS5A RCI or the NS5B NNI were unable to eradicate HCV RNA due to the emergent resistance variants, we analysed the effects of combining the NS5A RCI with either the NS3 PI or NS5B NNI. Mice infected with HCV genotype 1b (two mice per combination group) were treated with 10 mg/kg of BMS-788329 and either 75 mg/kg twice daily of BMS-605339 or 100 mg/kg of BMS-821095 for 4 weeks. In all mice, HCV RNA became negative by nested PCR 1 week after the beginning of combination therapy and remained undetectable after cessation of treatment ( figure 3A,B) . Elimination of the virus was assumed as HCV RNA was undetectable by nested PCR in mice livers treated with BMS-788329 and either BMS-605339 or BMS-821095 8 weeks (week 12) and 7 weeks (week 11) after cessation of therapy, respectively (figure 3C). We analysed the effect of DAA combination therapies on mice infected with HCV genotypes 2a and 2b. In contrast to mice with genotype 1b, mice with genotypes 2a or 2b failed to respond to 4 weeks of treatment with BMS-788329 and BMS-605339 ( figure 4A,B) . Although the combination of BMS-788329 with BMS-821095 revealed no detectable viral load decline at the time points examined in genotype 2a mice, viral load reductions were detected in genotype 2b mice.
Sequence analysis revealed no emergence of resistance variants in the NS3, NS5A or NS5B regions before and 4 weeks after the end of each of these combination treatments, suggesting insufficient drug selection pressure (data not shown).
DISCUSSION
DAA-only therapy may offer a promising option to eradicate HCV without incurring the severe side effects of Peg-alfa. However, the emergence of drug-resistant variants is expected for all DAA 21 and has already been observed in combination therapies with two DAA. 5 23 24 If the exposure of the drugs can be safely increased, as we recently reported for a two-drug combination administered to human hepatocyte chimeric mice, 12 eradication of virus is still possible. In this study, we tested the ability of different two-DAA combination therapies to eradicate HCV. Although DAA monotherapies resulted in a viral breakthrough due to the development of a high prevalence of drug-resistant variants ( figure 2A-D) , DAA combination therapies with the NS5A RCI and either the NS3 PI or NS5B NNI were shown to eradicate virus successfully from HCV genotype 1b-infected mice with only 4 weeks of treatment (figure 3). These two-DAA combination treatments resulted in more rapid, robust declines within the first week of treatment when compared with the suboptimal antiviral responses from each of their respective monotherapies. Furthermore, regimens containing NS5A RCI appeared equally effective in treating mice chronically infected with hepatitis C genotype 1b.
In contrast to the rapid decrease in HCV RNA in mice infected with HCV genotype 1b, HCV genotype 2a and 2b-infected mice either did not respond or responded poorly to treatment with the NS5A RCI combined with either the NS3 PI or NS5B NNI ( figure 4A,B) . In this study, NS3 PI and NS5B NNI IC 50 values against genotype 1b were markedly more potent than against genotype 2a in cell culture systems (table 1) . These findings are consistent with previous experimental results that reported reduced activity of these drug classes against genotype 2.
25 -28 In clinical trials, telaprevir monotherapy was found to result in a rapid decrease in serum HCV RNA levels in patients infected with HCV genotype 2; however, another protease inhibitor, BILN-2061, was less effective in patients with HCV genotype 2 compared to genotype 1. 29 Sequence analysis revealed a pre-existing A156G variant in the NS3 region, a L31M variant in the NS5A region and a I482L variant in the NS5B region in both HCV genotypes 2a and 2b infecting strains used in this study (data not shown). These NS3-A156G and NS5A-L31M variants confer resistance to inhibitors with similar chemical structures to BMS-605339 and BMS-788329, respectively, in genotype 2a replicon cell culture assays. [30] [31] [32] Although BMS-788329 was very potent against the genotype-2a JFH-1 replicon (IC 50 0.014 nM; table 1), its activity was significantly less against other genotype 2a and 2b viruses, such as genotype 2a HC-J6CF. The loss in potency observed in these viruses is not surprising because these viruses have a methionine at NS5A amino acid residue 31. The IC 50 of a genotype 2a hybrid replicon containing HC-J6CF NS5A with L31M substitution is approximately 10 nM (data not shown). The minimal antiviral response in mice infected with genotypes 2a and 2b receiving treatments containing BMS-788329 with either BMS-605339 or BMS-821095 can therefore be explained by pre-existing NS3, NS5A and NS5B resistance variants. Nevertheless, it is possible that mice infected with wild-type genotype 2 viruses and subsequently treated with higher doses of each of these DAA in dual or even triple combination therapy may have resulted in more robust reductions in viral load. The human hepatocyte chimeric mouse model offers a viable approach for identifying effective DAA-only combinations that not only act against HCV genotype 1 but against all HCV genotypes.
In summary, we demonstrated that an NS5A RCI can be effectively combined with different inhibitor classes to cure human hepatocyte chimeric mice infected with HCV genotype 1b after 4 weeks of treatment. However, these treatment combinations were not effective against HCV genotype 2. Oral combinations incorporating an NS5A RCI might offer Peg-alfa-free treatment options for genotype 1b chronic hepatitis C patients. 
